Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

10.01 +0.01 (+0.05%)
Delayed Quote Updated: 11:13 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Absci (ABSI) Q2 2026 Earnings Call Transcript ↗
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. 
Via The Motley Fool
Topics Earnings
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances ↗
Via Chartmill
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 ↗
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Absci (ABSI) Q1 2026 Earnings Call Transcript ↗
Absci (ABSI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Absci (ABSI) Q4 2025 Earnings Call Transcript ↗
Absci (ABSI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
What's going on in today's after hours session ↗
Via Chartmill
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
10 AI Stocks Worth Buying Right Now ↗
Building an artificial intelligence (AI) portfolio means looking beyond the obvious megacap names. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Absci (ABSI) Q3 2025 Earnings Call Transcript ↗
Absci (ABSI) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk ↗
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype? 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
AI Revolutionizes Professional Services: A New Era for Doctors, Lawyers, and Consultants
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration ↗
Absci teams up with Oracle and AMD to enhance AI-driven drug discovery using high-performance GPUs. 
Via Benzinga
News headline image
Absci Sales Fall 54 Percent ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Absci Corp (NASDAQ:ABSI) Q2 2025 Earnings: Revenue Miss Sparks Market Selloff ↗
Absci Corp (ABSI) Q2 2025 earnings miss revenue estimates at $0.59M vs. $1.46M, EPS -$0.24. Stock drops 5% post-report despite strong cash position and pipeline progress. 
Via Chartmill
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.